NCT03489395 - A Pilot Study on Edoxaban for the Resolution of Left Atrial Thrombosis in Patients With Non-valvular Atrial Fibrillation | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 30, 2018

Primary Completion Date

December 31, 2020

Study Completion Date

April 30, 2021

Conditions

Atrial Fibrillation

Interventions

DRUG

Edoxaban

Edoxaban 60 mg once a day for 4 weeks. Edoxaban 30 mg/day in patients with body weight ≤60 kg, or with concomitant therapy with verapamil/quinidine/dronedarone.

Trial Locations (8)

35128

Policlinico AO di Padova, Padua

63074

Ospedale Madonna del Soccorso, San Benedetto del Tronto

66013

Università degli Studi G. D'Annunzio, Chieti

70021

"Ospedale generale regionale F. Miulli", Acquaviva delle Fonti

80078

Presidio Ospedaliero S. Maria delle Grazie, Pozzuoli

80131

Ospedale P. Monaldi, Napoli

81100

AORN S.ANNA e S.SEBASTIANO, Caserta

00128

Policlinico Universitario Campus Bio-Medico, Roma